Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -48.44% is 40% below its 5-year average of -34.60%, near the low end of its 5-year range (-48.44%–-23.02%).
13.96% below its 12-month average of -42.51%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.60%.
RETURN ON ASSETS (ROA)
-48.44%
RETURN ON ASSETS (ROA) AVG TTM
-42.51%
RETURN ON ASSETS (ROA) AVG 3Y
-39.18%
RETURN ON ASSETS (ROA) AVG 5Y
-34.60%
RETURN ON ASSETS (ROA) AVG 10Y
-35.59%
RETURN ON ASSETS (ROA) AVG 15Y
-36.89%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.96%
CURRENT VS 3Y AVG
-23.63%
CURRENT VS 5Y AVG
-39.99%
CURRENT VS 10Y AVG
-36.11%
CURRENT VS 15Y AVG
-31.30%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-50.25%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$271.00M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$271.35M
Return on Assets (ROA)
-4.08%
TTM Avg
-58.27%
3Y Avg
-50.03%
5Y Avg
-43.16%
Market Cap
$270.52M
Return on Assets (ROA)
-32.87%
TTM Avg
-28.32%
3Y Avg
-25.80%
5Y Avg
-21.10%
Market Cap
$270.30M
Return on Assets (ROA)
-66.64%
TTM Avg
-23.99%
3Y Avg
-11.65%
5Y Avg
-6.11%
Market Cap
$270.68M
Return on Assets (ROA)
-5.36%
TTM Avg
-34.75%
3Y Avg
-39.14%
5Y Avg
-23.69%
Market Cap
$269.70M
Return on Assets (ROA)
-45.18%
TTM Avg
-124.83%
3Y Avg
-176.38%
5Y Avg
-195.56%
Market Cap
$267.08M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.73M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$264.44M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $271.00M | -48.44% | -42.51% | -39.18% | -34.60% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | -4.08% | -58.27% | -50.03% | -43.16% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | -32.87% | -28.32% | -25.80% | -21.10% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.30M | -66.64% | -23.99% | -11.65% | -6.11% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.68M | -5.36% | -34.75% | -39.14% | -23.69% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.70M | -45.18% | -124.83% | -176.38% | -195.56% |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.08M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | -37.07% | -27.27% | -64.53% | -52.03% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.44M | -134.38% | -47.50% | -42.91% | -40.55% |
| Palisade Bio, Inc. (PALI)vs › | $263.36M | -25.09% | -72.59% | -80.80% | -146.30% |
ROA
-48.4%
ROE
-82.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -42.74% |
| 2024-12-31 | -42.27% |
| 2023-12-31 | -31.79% |
| 2022-12-31 | -39.93% |
| 2021-12-31 | -23.02% |
| 2020-12-31 | -27.86% |
| 2019-12-31 | -32.47% |
| 2018-12-31 | -31.26% |
| 2017-12-31 | -40.79% |
| 2016-12-31 | -35.21% |
| 2015-12-31 | -44.13% |
| 2014-12-31 | -50.55% |
| 2013-12-31 | -37.59% |
| 2012-12-31 | -128.56% |
| 2011-12-31 | -171.00% |
